Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Nasdaq6d
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
How might Medicare price negotiations impact Novo Nordisk's battle in the marketplace with Eli Lilly? Lilly's type 2 diabetes drug Mounjaro and obesity drug Zepbound aren't eligible for Medicare ...
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
Eli Lilly's SWOT analysis: stock poised for growth amid challenges
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...
Eli Lilly: Market Overreacted
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Investors lose their appetite for the obesity trade
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
Zacks.com on MSN5d
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney ...
What’s behind the meteoric rise of weight-loss drugs in Massachusetts?
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...